Hangzhou Tigermed Consulting Co., Ltd. (TIGERMED) has signed three definitive agreements that will lead to the privatisation of its Hong Kong-listed subsidiary Frontage Holdings Corporation and the subsequent divestment of Frontage’s overseas laboratory services business.
Key Transaction Structure • Consortium formation: TIGERMED’s Hongkong Tigermed unit, Charles River Laboratories International (CRL) and Frontage founder Dr. Song Li have formed SanRex Ltd. (the “Offeror”), incorporated in the Cayman Islands. Current ownership: CRL 38.27%, Hongkong Tigermed 53.40%, Dr. Li and related trusts 8.35%. • Privatisation proposal: The Offeror will acquire all 2.04 billion Frontage shares via a Cayman scheme of arrangement at HKD 2.370 per share. TIGERMED’s 64.48% stake (1.31 billion shares) will be cancelled; the company itself will receive HKD 535.67 million (≈RMB 461.20 million) in cash for its directly held 226.02 million shares, while Hongkong Tigermed’s 1.09 billion shares will be exchanged for fully-paid Offeror shares. • Option Offer: 79.09 million outstanding Frontage options will be cancelled for a “see-through” cash payment; options where exercise prices exceed the HKD 2.370 offer will be bought for HKD 0.0001 each. • Earn-outs: Former Frontage shareholders and option holders may receive up to USD 50 million for FY-2026 and up to USD 25 million for FY-2027, conditional on revenue and EBITDA margin thresholds for the Target Business.
Separation Transaction Highlights Post-privatisation, TIGERMED will divest Frontage’s non-China laboratory assets to CRL and Dr. Li while retaining Frontage International Limited and all PRC laboratory assets. Key steps include: 1. Asset Restructuring—segregation of target (bioanalysis and DMPK) and non-target assets. 2. Adjustment of Ownership—cash settlements and share redemptions recalibrate equity in the Offeror based on pre-agreed valuations (Target: USD 470.00 million; Non-Target Non-China: USD 84.40 million; Non-Target China: USD 205.50 million). 3. Equity Transfer—Offeror will distribute 100% of Frontage Research (non-China assets) to Frontage ACE (Dr. Li) and 100% of Frontage International Limited (PRC assets) to Hongkong Tigermed; CRL will own 100% of the Offeror and Frontage Holdings thereafter.
Financial Impact on TIGERMED • Immediate cash inflow: HKD 535.67 million from cancellation of Company Scheme Shares, plus additional cash from shareholding adjustments (to be finalised post-closing). • Profit recognition: TIGERMED expects to book a gain of no less than RMB 500.00 million from the divestment of overseas assets and related transactions, after intra-group eliminations. • Proceeds allocation: 60% earmarked for overseas clinical CRO expansion and acquisitions, 20% for general corporate purposes, and up to 20% potentially for future dividends or share buy-backs, subject to board and shareholder approvals.
Regulatory & Shareholder Approvals • Hong Kong: Transactions constitute discloseable and subsidiary-level connected transactions, requiring public disclosure but exempt from shareholder approval under the Listing Rules. • Shenzhen: As anticipated profit exceeds 50% of last year’s audited net profit, the deals require approval at TIGERMED’s extraordinary general meeting (EGM). • EGM commitments: Major shareholders Dr. Ye Xiaoping and Ms. Cao Xiaochun (holding 228.55 million A-shares) have irrevocably undertaken to vote in favour of all resolutions.
Timetable & Conditions The privatisation is contingent on multiple pre-conditions (including TIGERMED shareholder approval and U.S. antitrust clearance) and court, regulatory and shareholder approvals. The scheme long-stop date is 30 June 2027, extendable by mutual agreement.
Post-Transaction Structure On completion of the Separation Transaction, CRL will control 100% of Frontage Holdings and the Offeror, while TIGERMED will deconsolidate Frontage’s overseas assets and liabilities, retaining China-based laboratory operations through Frontage International Limited.
Comments